Treatment of juvenile rheumatoid arthritis / 소아과
Korean Journal of Pediatrics
;
: 936-941, 2010.
Artículo
en Inglés
| WPRIM
| ID: wpr-7281
ABSTRACT
The systematic approach to pharmacologic treatment is typically to begin with the safest, simplest, and most conservative measures. It has been realized that the more rapidly inflammation is under control, the less likely it is that there will be permanent sequelae. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of initial treatment for inflammation. In addition, the slow-acting antirheumatic drugs (SAARDs) and disease-modifying antirheumatic drugs (DMARDs) have efficacy of anti-inflammatory action in children with chronic arthritis. New therapeutic modalities for inflammation, such as etanercept and infliximab, promise even further improvements in the risk/benefit ratio of treatment. It is not typically possible at the onset of the disease to predict which children will recover and which will go on to have unremitting disease with lingering disability or enter adulthood with serious functional impairment. Therefore, the initial therapeutic approach must be vigorous in all children.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Artritis
/
Artritis Juvenil
/
Inmunoglobulina G
/
Antiinflamatorios no Esteroideos
/
Receptores del Factor de Necrosis Tumoral
/
Antirreumáticos
/
Infliximab
/
Etanercept
/
Inflamación
/
Anticuerpos Monoclonales
Tipo de estudio:
Estudio pronóstico
Límite:
Niño
/
Humanos
Idioma:
Inglés
Revista:
Korean Journal of Pediatrics
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS